fig4

Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance

Figure 4. Differences in the immune microenvironment and immune therapy response among the three subtypes. (A) Immune cell infiltration landscape across different clusters; (B) Differences in the expression levels of immune regulatory molecules in multiple cohorts, including Beat-AML, GSE71014, GSE10358, and GSE14468; (C) Differences in T cell states in the TCGA-LAML cohort; (D) Evaluation of immune therapy response across different clusters in the Beat-AML, GSE71014, GSE37642, and GSE14468 cohorts. Differences among three or more groups were assessed with the Kruskal-Wallis test, categorical variables were analyzed using the chi-square test or Fisher’s exact test. P < 0.05 was considered statistically significant. ns indicates not significant. AML: Acute myeloid leukemia; TCGA-LAML: The Cancer Genome Atlas-Acute Myeloid Leukemia; NK: natural killer.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/